- Home
- INBX vs NEO Comparison
INBX vs NEO Comparison
Compare INBX & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INBX | NEO |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.7M | 1.0B |
| IPO Year | 2024 | 2008 |
Fundamental Metrics
Financial Performance| Metric | INBX | NEO |
|---|---|---|
| Price | $80.86 | $8.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $150.00 | $11.14 |
| AVG Volume (30 Days) | 220.4K | ★ 1.5M |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,300,000.00 | N/A |
| Revenue This Year | N/A | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 550.00 | N/A |
| 52 Week Low | $10.90 | $4.72 |
| 52 Week High | $94.57 | $13.74 |
Technical Indicators
Market Signals| Indicator | INBX | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 46.34 |
| Support Level | $71.31 | $7.84 |
| Resistance Level | $85.97 | $8.89 |
| Average True Range (ATR) | 5.48 | 0.46 |
| MACD | 2.29 | 0.14 |
| Stochastic Oscillator | 71.98 | 57.61 |
Price Performance
Historical ComparisonAbout INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.